Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Posted: September 8, 2022 at 2:03 am

SAINT-HERBLAIN, France and CAMBRIDGE, Mass. (September 8, 2022) – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.

The rest is here:
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Related Posts